Join the club for FREE to access the whole archive and other member benefits.

Cleara Biotech

Cleara is developing therapeutics to eliminate senescent cells.

Cleara Biotech discovered a mechanism that shows how senescent cells escape the natural elimination process. Based on this discovery, Cleara is developing therapeutics to treat patients with a range of diseases caused by this failure to clear senescent cells.

Visit website: https://www.clearabiotech.com/

 Login to view link, or join the club to get full access to all resources and other benefits.

 Login to view link, or join the club to get full access to all resources and other benefits.

Cleara Biotech News

LMC provides background and success outlook on 14 leading senolytic companies

Longevity Marketcap - 15-Dec-2020

Comprehensive review of companies' clinical and financial state of play

Read more...

Nature Biotechnology reviews the state of play of senolytics

Nature Biotechnology - 12-Nov-2020

In August, Unity announced that its lead drug candidate had failed to beat a placebo in reducing ...

Read more...

Labiotech gathers feedback from European biotechs on Unity failure

Labiotech - 28-Aug-2020

General feeling that failures are bound to happen - but that their approaches can succeed

Read more...

LEAF report from the Longevity Leaders Conference

Lifespan.io (LEAF) - 06-Feb-2019

Encouraging signs from big companies - more interviews to follow

Read more...

Cleara Biotech Joins the Race to Develop Senolytic Therapies

Lifespan.io (LEAF) - 09-Jul-2018

This therapy uses a modified FOXO4 to promote apoptosis in senescent cells

Read more...